TrialThe Lancet. Oncology2016

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Keunchil Park et al.PubMed ↗Publisher ↗

No numbers read from the abstract.